Glenmark partners with SaNOtize for Covid-19 nasal spray
SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections in 2017.
The drugmaker Glenmark Pharmaceuticals has signed an agreement with Canadian biotech firm SaNOtize Research and Development Corp to produce its nitric oxide nasal spray for Covid-19 treatment in India and other Asian markets.
The strategic partnership is aimed to manufacture, market, and distribute SaNOtize’s Nitric Oxide Nasal Spray (NONS) in Asian markets including India, Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor Leste, and Vietnam.
Early July 2021, Glenmark had submitted a proposal to the subject expert committee of CDSCO for emergency approval for the import and marketing of the nasal spray.
“The committee has recommended a phase III clinical trial to be conducted in Indian patients in the weeks to follow. The phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand name FabiSpray in India, by the fourth quarter of the calendar year 2021,” the company added.
“This partnership with SaNOtize closely aligns with Glenmark’s focused approach against Covid-19 and will help reduce the burden of the pandemic in the region,” said Glenn Saldanha, CMD, Glenmark Pharmaceuticals.
SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections in 2017. It aims to bring in much needed therapeutic relief to patients in India and Asia